Neuraxpharm expands its business in South East Europe. The pharmaceutical company specializing in the treatment of central nervous system (CNS) disorders has acquired Brain Therapeutics, a Greek marketing and distribution company specialized in the CNS with experience in marketing products for Greece, Cyprus and the Balkan countries. The terms of the transaction have not been disclosed.
Headquartered in Athens, Brain Therapeutics specializes in the licensing and commercialization of pharmaceuticals in the CNS therapeutic area to address the unmet medical needs of patients with mental, neurological, neurodevelopmental or neurodegenerative disorders, as well as anesthesia and pain.
With the acquisition of Brain Therapeutics, Neuraxpharm may introduce new products on the Greek market, by having a platform that offers a unique level of access to the local market. Brain Therapeutics’ commercial expertise and the availability of the necessary licenses for its extensive product portfolio will enable Neuraxpharm to rapidly expand its offering and grow its position as a CNS specialist in the South East Europe area. The product for the emergency treatment of children and adolescents with epilepsy, Buccolamwill also be among the products to be distributed, according to Neuraxpharm in a statement.
Neuraxpharm has expanded its activities from two to 19 European countries in five years
Neuraxpharm has expanded its activities from two to 19 European countries in five years, five of which have been added in the last twelve months. The Greek market in the SNC area, with 4% growth in 2020represents “an excellent opportunity for Neuraxpharm to further expand its presence in Europe”, explains the company in the note.
Jörg-Thomas Dierks, CEO of Neuraxpharm, comments that “the acquisition of Brain Therapeutics will significantly strengthen our activity in the commercialization of CNS products in Greece, Cyprus and the Balkan countries; We are excited to be able to supply our products to patients in South East Europe more efficiently from now on.”
George Pavlakis, founder of Brain Therapeutics, adds that “we are excited regarding our future with the Neuraxpharm Group and the opportunity to contribute our expertise in the CNS field; Together, we will be able to offer more innovative CNS products to patients in Greece and South East Europe.”
George Pavlakis will be the CEO of Neuraxpharm in Greece and other countries in this geographical area that will gradually join this new commercial area of the company, Neuraxpharm details.
